| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
41,210,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile IMARA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies, and other serious diseases. Co.'s pipeline is built on the differentiated therapeutic potential of its primary product candidate, tovinontrine (IMR-687), which is an oral, small molecule inhibitor of phosphodiesterase-9. Tovinontrine is in Phase 2b clinical development for the treatment of sickle cell disease and ss-thalassemia. Co. is also developing IMR-261, an oral, clinic-ready activator of nuclear factor erythroid 2–related factor 2.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,441,450 |
| Total Buy Value |
$0 |
$0 |
$0 |
$5,187,327 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
17 |
| Total Shares Sold |
323,348 |
1,774,167 |
2,254,739 |
4,902,365 |
| Total Sell Value |
$7,115,436 |
$28,736,312 |
$36,322,251 |
$46,944,341 |
| Total People Sold |
7 |
8 |
8 |
10 |
| Total Sell Transactions |
29 |
63 |
68 |
79 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Heyman Richard A. |
Director |
– • – |
2023-12-20 |
4 |
AS |
$13.02 |
$27,473 |
D/D |
(2,110) |
147,455 |
|
- |
|
| Lyssikatos Joseph P |
Chief Scientific Officer |
• • – |
2023-12-19 |
4 |
AS |
$13.00 |
$2,600 |
D/D |
(200) |
0 |
|
- |
|
| Lyssikatos Joseph P |
Chief Scientific Officer |
• • – |
2023-12-19 |
4 |
OE |
$1.12 |
$224 |
D/D |
200 |
200 |
|
- |
|
| Heyman Richard A. |
Director |
– • – |
2023-12-19 |
4 |
AS |
$13.00 |
$3,315 |
D/D |
(255) |
149,565 |
|
- |
|
| Lyssikatos Joseph P |
Chief Scientific Officer |
• • – |
2023-11-03 |
4 |
AS |
$13.08 |
$111,751 |
D/D |
(8,546) |
0 |
|
- |
|
| Lyssikatos Joseph P |
Chief Scientific Officer |
• • – |
2023-11-03 |
4 |
OE |
$1.12 |
$9,572 |
D/D |
8,546 |
8,546 |
|
- |
|
| Kintz Samuel |
President and CEO |
• • – |
2023-11-03 |
4 |
AS |
$13.08 |
$104,999 |
D/D |
(8,026) |
0 |
|
- |
|
| Kintz Samuel |
President and CEO |
• • – |
2023-11-03 |
4 |
OE |
$1.12 |
$8,989 |
D/D |
8,026 |
8,026 |
|
- |
|
| Lyssikatos Joseph P |
Chief Scientific Officer |
• • – |
2023-09-29 |
4 |
AS |
$13.62 |
$163,498 |
D/D |
(12,000) |
0 |
|
- |
|
| Lyssikatos Joseph P |
Chief Scientific Officer |
• • – |
2023-09-29 |
4 |
OE |
$1.12 |
$13,440 |
D/D |
12,000 |
12,000 |
|
- |
|
| Kintz Samuel |
President and CEO |
• • – |
2023-09-25 |
4 |
AS |
$13.81 |
$165,691 |
D/D |
(12,000) |
0 |
|
- |
|
| Kintz Samuel |
President and CEO |
• • – |
2023-09-25 |
4 |
OE |
$1.12 |
$13,440 |
D/D |
12,000 |
12,000 |
|
- |
|
| Schwab Andrew J. |
10% Owner |
– – • |
2023-08-24 |
4 |
S |
$16.00 |
$7,040,000 |
I/I |
(440,000) |
887,507 |
|
- |
|
| Gupta Rishi |
Director |
– • • |
2023-05-17 |
4 |
OE |
$4.28 |
$9,095 |
I/I |
2,125 |
8,663,349 |
|
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • • |
2023-05-17 |
4 |
OE |
$4.28 |
$9,095 |
I/I |
2,125 |
8,663,349 |
|
- |
|
| Parmar Kush |
10% Owner |
– – • |
2023-02-23 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,798,475 |
|
- |
|
| Orbimed Genesis Gp Llc |
10% Owner |
– – • |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
I/I |
7,899,572 |
288,114 |
|
- |
|
| Gupta Rishi |
Director |
– • • |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
I/I |
7,899,572 |
288,114 |
|
- |
|
| Commodore Capital Lp |
10% Owner |
– – • |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
I/I |
729,891 |
1,448,640 |
|
- |
|
| Commodore Capital Lp |
10% Owner |
– – • |
2023-02-23 |
4 |
B |
$22.07 |
$13,723 |
I/I |
622 |
718,749 |
1.5 |
- |
|
| Patel Anish |
Chief Operating Officer |
• – – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
I/I |
394,027 |
394,027 |
|
- |
|
| Patel Anish |
Chief Operating Officer |
• – – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
36,722 |
36,722 |
|
- |
|
| Shah Rajeev M. |
Former 10% owner |
– – – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
I/I |
1,152,460 |
2,122,465 |
|
- |
|
| Bauer Jake |
Director |
– • – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
87,372 |
87,372 |
|
- |
|
| Schwab Andrew J. |
Director |
– • – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
I/I |
5,798,475 |
960,383 |
|
- |
|
247 Records found
|
|
Page 5 of 10 |
|
|
